HCVELIMINATION

When it comes to global hepatitis C virus (HCV) elimination, we believe time matters. We are less than 10 years away from the World Health Organization (WHO) 2030 goal for HCV elimination.1

HCV elimination is achievable, but we must work together to maximize the time we have left.



Previously it had been known only as non-A non-B hepatitis (NANBH)²





Interferon, the first treatment for chronic hepatitis C, is approved. This treatment is administered by injection and the treatment course typically lasts between 24 and 48 weeks4

2007



Deaths from hepatitis C surpass those from HIV, in the US⁶

The World Hepatitis Alliance is founded⁷

2011



The first WHO official World Hepatitis Day is held on the 28th July⁷

First generation DAAs, called protease inhibitors, used in combination with pegylated interferon and ribavirin are developed to treat chronic HCV.9


2016



Pan-genotypic (genotypes 1-6) DAA treatments become available¹⁰


The WHO sets the goal for the global elimination of HCV by 20301

2018



AbbVie enters into agreement with the Medicines Patent Pool (MPP) to expand access to HCV treatments in low- and middle-income territories¹⁴

2020 **AND BEYOND**





people are living with chronic HCV¹⁶ Of those 71 million, 14 million —

are aware of their diagnosis 1.76 million of those diagnosed -

start treatment¹⁷ AbbVie is supporting an estimated


300 micro-elimination projects (including 53 studies) worldwide¹²

AbbVie broadens its support of



the Coalition for Global Hepatitis Elimination with a new grant to expand the coalition's reach and overall awareness

ABBVIE STORIES How a world free from viral




The Next Frontier Going inside prison walls to

help eliminate hepatitis C HCV micro-elimination:

holistic approach to care in people who inject drugs

Hear from some of AbbVie's partners on: The importance of partnership



HCV care The urgency to act now to

eliminate HCV What they think it will take

to achieve HCV elimination

1989 The hepatitis C virus is identified.

1990

Screening blood for hepatitis C begins in the US, reducing the risk of transmission through transfusion³



1998

A treatment for hepatitis C using a combination of interferon and ribavirin is approved⁵



2010

The first rapid antibody test for hepatitis C detection becomes available. Delivering results in just 20 minutes8



2014

Combination DAA treatments are introduced, allowing for the first interferon-free, entirely oral treatment for some patients (genotype 1)9



2017

AbbVie Partnership with the **Economist Intelligence Unit:** The Path to Zero initiative to foster a global dialogue around innovative solutions towards HCV elimination¹¹



In collaboration with viral hepatitis

experts, AbbVie launches MappingHepC.com, an interactive online resource that features national and state-level US epidemiology data on HCV screening, diagnosis and treatment. This increased understanding of the patient landscape is a crucial step towards eliminating the virus in the US¹³



2019

AbbVie becomes a member of the Coalition for Global Hepatitis Elimination¹⁵



1. World Health Organization, 2016. Draft global health sector strategies Viral hepatitis, 2016–2021. Available from: https://apps.who.int/gb/ebwha/pdf_-

References

files/WHA69/A69_32-en.pdf?ua=1 Last accessed 2nd June 2020 2. Bukh J, 2016. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new per-

spectives for epidemic control. Journal of hepatology. Oct 1;65(1): S2-1. 3. Selvarajah S, Busch MP, 2012. Transfusion transmission of HCV, a long but

successful road map to safety. Antivir Ther. 17(7 Pt B):1423-1429. 4. Dahiya M, et al, 2019. The Revolutionary Changes in Hepatitis C Treatment: A

5. Baker R, 1998. FDA approves new combination treatment for hepatitis C. Food and Drug Administration. BETA. 1998;10.

Concise Review. BCMJ, vol. 61, No. 2, (72-77).

6. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD, 2012. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of internal medicine. 21;156(4):271-8. Feb

7. Wold Hepatitis Alliance. Our Story. Available from: https://www.worldhepatiti-

salliance.org/about/our-story Last accessed 2nd June 2020 8. Medscape, 2010. FDA Approves First Rapid HCV Antibody Test. Available from: https://www.medscape.com/viewarticle/724236 Last accessed 2nd June 2020

9. PhRMA, 2014. Twenty-Five Years of Progress Against Hepatitis C; Setbacks and Stepping Stones. Available: http://phrma-docs.phrma.org/sites/default/files/pdf/Hep-C-Report-2014-Stepping-Stones.pdf Last accessed 2nd June 2020

10. World Health Organization, 2018. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic hepatitis C Virus Infection. Available from: https://apps.who.int/iris/bitstream/handle/10665/

273174/9789241550345-eng.pdf?ua=1. Last accessed 2nd June 2020 11. AbbVie News Centre, 2017. Can Hepatitis C Be Eliminated by 2030? On the Path to Zero. Accessed from: https://news.abbvie.com/news/abbvie-news-briefs/can-hepatitis-c-be-eliminated-by-2030-on-path-to-zero.htm

Last Accessed 18 June, 2020 12. Calleja et al, 2019. Eliminating Hepatitis C by 2030: The Role of AbbVie.

Available from: https://www.abbvie.com/content/dam/abbvie-dotcom/up-

loads/PDFs/virology/hcv-elimination-overview.pdf Last accessed: 18th June 2020 13. AbbVie News Center, 2018. Available from:

https://news.abbvie.com/news/press-releases/abbvie-characterizes-evolving-hepatitis-c-hcv-patient-landscape-in-united-states-using-co mprehensive-dataset.htm. Last accessed 2nd June 2020

14. Medicines Patent Pool, 2018. The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir. Available from: https://www.prnewswire.com/news-releases/the-medicines-patent-pool-signs-licence-

with-abbvie-to-expand-access-to-key-hepatitis-c-treatment-glecaprevir-pibrentasvir-889601742.html Last accessed 17th June 2020

15. Coalition for Global Hepatitis Elimination Donor Acknowledgments: https://www.globalhep.org/about/donor-acknowledgements

16. World Health Organization, 2019. Factsheet: Hepatitis C. Available from:

17th June 2020

https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Last accessed

2nd June 2020

17. World Health Organization, 2018. Progress Report on Access to Hepatitis C Treatment. Available from: https://apps.who.int/iris/bitstream/handle/10665/260445/WHO-CDS-HIV-18.4-eng.pdf?sequence=1 Last accessed